CLL Exchange Bite-sized: Fixed-duration decision making in 1L CLL.
Join Dr Renata Walewska discussing how decision making is evolving when selecting a fixed-duration treatment option for 1L CLL.
Adverse events should be reported
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
September 2025 I GB-69434